Compare WST & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WST | HOLX |
|---|---|---|
| Founded | 1923 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6B | 16.6B |
| IPO Year | 2004 | 1995 |
| Metric | WST | HOLX |
|---|---|---|
| Price | $250.97 | $75.47 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 13 |
| Target Price | ★ $319.43 | $77.89 |
| AVG Volume (30 Days) | 949.4K | ★ 2.2M |
| Earning Date | 05-15-2026 | 04-27-2026 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | ★ 1.49 | N/A |
| EPS | ★ 6.79 | 0.79 |
| Revenue | $2,886,900,000.00 | ★ $4,100,500,000.00 |
| Revenue This Year | $6.83 | $4.74 |
| Revenue Next Year | $6.18 | $5.03 |
| P/E Ratio | ★ $37.00 | $95.50 |
| Revenue Growth | ★ 1.95 | 1.74 |
| 52 Week Low | $187.43 | $51.90 |
| 52 Week High | $322.34 | $75.49 |
| Indicator | WST | HOLX |
|---|---|---|
| Relative Strength Index (RSI) | 52.31 | 62.81 |
| Support Level | $244.30 | $74.53 |
| Resistance Level | $261.98 | N/A |
| Average True Range (ATR) | 8.31 | 0.21 |
| MACD | 1.82 | 0.02 |
| Stochastic Oscillator | 72.45 | 95.87 |
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.